VEA
IRWD icon

Virtus ETF Advisers’s Ironwood Pharmaceuticals IRWD Stock Holding History

Virtus ETF Advisers’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Hold
58,000
– – 0.09% 234
2025
Q4 		$195K Buy
+58,000
New +$151K 0.09% 246
2025
Q1 		– Sell
-98,218
Closed -$435K – 608
2024
Q4 		$435K Buy
98,218
+43,143
+78% +$175K 0.18% 187
2024
Q3 		$227K Hold
55,075
– – 0.11% 244
2024
Q2 		$359K Buy
55,075
+21,798
+66% +$154K 0.18% 190
2024
Q1 		$290K Buy
33,277
+4,788
+17% +$58.1K 0.15% 228
2023
Q4 		$326K Buy
28,489
+951
+3% +$9.41K 0.21% 209
2023
Q3 		$265K Sell
27,538
-3,559
-11% -$34.9K 0.16% 217
2023
Q2 		$331K Buy
31,097
+6,259
+25% +$67.3K 0.2% 175
2023
Q1 		$261K Buy
24,838
+439
+2% +$4.92K 0.14% 274
2022
Q4 		$302K Buy
24,399
+3,829
+19% +$43.4K 0.16% 265
2022
Q3 		$213K Buy
20,570
+303
+1% +$3.44K 0.08% 314
2022
Q2 		$234K Sell
20,267
-13,795
-40% -$163K 0.09% 311
2022
Q1 		$428K Hold
34,062
– – 0.19% 145
2021
Q4 		$397K Sell
34,062
-6,633
-16% -$81.4K 0.15% 153
2021
Q3 		$531K Sell
40,695
-3,726
-8% -$48.2K 0.23% 129
2021
Q2 		$572K Sell
44,421
-6,890
-13% -$78.9K 0.24% 116
2021
Q1 		$574K Buy
51,311
+1,403
+3% +$14.8K 0.24% 133
2020
Q4 		$568K Sell
49,908
-14,038
-22% -$154K 0.24% 127
2020
Q3 		$575K Buy
63,946
+5,386
+9% +$53.5K 0.3% 117
2020
Q2 		$604K Buy
58,560
+12,557
+27% +$129K 0.29% 118
2020
Q1 		$464K Sell
46,003
-3,882
-8% -$45.6K 0.19% 177
2019
Q4 		$664K Sell
49,885
-16,931
-25% -$187K 0.11% 162
2019
Q3 		$574K Sell
66,816
-11,244
-14% -$109K 0.12% 177
2019
Q2 		$854K Sell
78,060
-4,100
-5% -$45.9K 0.18% 167
2019
Q1 		$931K Buy
82,160
+19,091
+30% +$213K 1.98% 12
2018
Q4 		$547K Buy
63,069
+12,766
+25% +$147K 0.09% 70
2018
Q3 		$778K Buy
50,303
+3,390
+7% +$53.6K 0.08% 67
2018
Q2 		$751K Sell
46,913
-23,550
-33% -$349K 0.66% 70
2018
Q1 		$911K Sell
70,463
-4,162
-6% -$51.9K 0.79% 57
2017
Q4 		$937K Buy
74,625
+4,960
+7% +$64.8K 1.18% 37
2017
Q3 		$920K Hold
69,665
– – 0.12% 66
2017
Q2 		$1.1M Sell
69,665
-9,330
-12% -$136K 0.16% 48
2017
Q1 		$1.13M Buy
78,995
+7,596
+11% +$104K 0.2% 56
2016
Q4 		$914K Buy
71,399
+13,643
+24% +$172K 0.27% 67
2016
Q3 		$768K Buy
57,756
+7,277
+14% +$85.1K 0.37% 46
2016
Q2 		$553K Sell
50,479
-13,744
-21% -$134K 0.41% 35
2016
Q1 		$588K Buy
+64,223
New +$530K 0.81% 27

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtus ETF Advisers's IRWD Position: Q1 2026 in Review

Virtus ETF Advisers held its Ironwood Pharmaceuticals (IRWD) position steady in Q1 2026 at 58,000 shares worth $204K. The position accounts for 0.09% of the portfolio, ranked #234.

Virtus ETF Advisers first reported a position in IRWD in Q1 2016 and has held it in 38 quarters since. The position peaked at $1.13M in Q1 2017. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Virtus ETF Advisers held 58,000 shares of Ironwood Pharmaceuticals worth $204K as of Q1 2026.
  • Virtus ETF Advisers left its Ironwood Pharmaceuticals share count unchanged in Q1 2026.
  • Ironwood Pharmaceuticals made up 0.09% of Virtus ETF Advisers's portfolio in Q1 2026, its #234 holding.
  • Virtus ETF Advisers first reported a position in Ironwood Pharmaceuticals in Q1 2016 and has held it in 38 quarters since.
  • Virtus ETF Advisers's Ironwood Pharmaceuticals position peaked at $1.13M in Q1 2017.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.